In this issue of Clinics in Liver Disease, guest editor Robert G. Gish brings his considerable expertise to the topic of Hepatitis B and Hepatitis D. The articles provide state-of-the-art clinical summaries of the advances in Hepatitis B and D, with emphasis on HBV viro-immunology, novel assays, new targets, and tests for HBV and HDV, and more.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. xi 7. Preface - p. xiii 8. Hepatitis B - p. xiv 9. Chronic Hepatitis B: Treat all Who Are Viremic? - p. 791 10. Are the New Nucleos(t)ide Analogs Better than the Old Nucleos(t)ide Analogs? - p. 809 11. What Is the Current Status of Hepatitis B Virus Viro-Immunology? - p. 819 12. Novel Assays to Solve the Clinical and Scientific Challenges of Chronic Hepatitis B - p. 837 13. Overview of New Targets for Hepatitis B Virus: Immune Modulators, Interferons, Bifunctional Peptides, Therapeutic Vaccines and Beyond - p. 857 14. Novel Drug Development in Chronic Hepatitis B Infection: Capsid Assembly Modulators and Nucleic Acid Polymers - p. 877 15. Targeting Hepatitis B Virus DNA Using Designer Gene Editors - p. 895 16. Delta Hepatitis - p. 916 17. Maternal-to-Child Transmission of Hepatitis B Virus and Hepatitis Delta Virus - p. 917 18. State of the Art: Test all for Anti-Hepatitis D Virus and Reflex to Hepatitis D Virus RNA Polymerase Chain Reaction Quantification - p. 937 19. Triple Threat: HDV, HBV, HIV Coinfection - p. 955 20. What Is the Real Epidemiology of Hepatitis D Virus and Why so Many Mixed Messages? - p. 973 21. What is the Path Forward to Treat Hepatitis Delta Virus?: Old Treatments and New Options - p. 985 22. Back to “B” - p. 995 23. Test All for Hepatitis B Virus: Link to Care and Treatment if Quantitative DNA Positive, Vaccinate if Susceptible - p. 997
In this issue of Clinics in Liver Disease, guest editor Robert G. Gish brings his considerable expertise to the topic of Hepatitis B and Hepatitis D. The articles provide state-of-the-art clinical summaries of the advances in Hepatitis B and D, with emphasis on HBV viro-immunology, novel assays, new targets, and tests for HBV and HDV, and more.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. xi 7. Preface - p. xiii 8. Hepatitis B - p. xiv 9. Chronic Hepatitis B: Treat all Who Are Viremic? - p. 791 10. Are the New Nucleos(t)ide Analogs Better than the Old Nucleos(t)ide Analogs? - p. 809 11. What Is the Current Status of Hepatitis B Virus Viro-Immunology? - p. 819 12. Novel Assays to Solve the Clinical and Scientific Challenges of Chronic Hepatitis B - p. 837 13. Overview of New Targets for Hepatitis B Virus: Immune Modulators, Interferons, Bifunctional Peptides, Therapeutic Vaccines and Beyond - p. 857 14. Novel Drug Development in Chronic Hepatitis B Infection: Capsid Assembly Modulators and Nucleic Acid Polymers - p. 877 15. Targeting Hepatitis B Virus DNA Using Designer Gene Editors - p. 895 16. Delta Hepatitis - p. 916 17. Maternal-to-Child Transmission of Hepatitis B Virus and Hepatitis Delta Virus - p. 917 18. State of the Art: Test all for Anti-Hepatitis D Virus and Reflex to Hepatitis D Virus RNA Polymerase Chain Reaction Quantification - p. 937 19. Triple Threat: HDV, HBV, HIV Coinfection - p. 955 20. What Is the Real Epidemiology of Hepatitis D Virus and Why so Many Mixed Messages? - p. 973 21. What is the Path Forward to Treat Hepatitis Delta Virus?: Old Treatments and New Options - p. 985 22. Back to “B” - p. 995 23. Test All for Hepatitis B Virus: Link to Care and Treatment if Quantitative DNA Positive, Vaccinate if Susceptible - p. 997
